secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001213900-25-120691
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q1 FY2026 net loss $9.8M; Phase 3 NPC trial continues
---------------------------------------------------------------------

- Net loss attributable to Rafael Holdings of $9.8M ($0.19/shr), widened from $9.0M ($0.37/shr) YoY.
- R&D expenses $7.5M vs $1.3M YoY, driven by Cyclo Therapeutics consolidation after March 2025 acquisition.
- Cash and cash equivalents $45.5M as of October 31, 2025.
- CEO Howard Jonas highlighted Phase 3 TransportNPC study for Trappsol Cyclo; DMC recommended continue after 48-week data.
- General & administrative expenses $2.8M vs $2.5M YoY, also due to Cyclo consolidation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/0001213900-25-120691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea0269127-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-120691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer